Year Founded
2014
Ownership
Private
Employees
~10
Stage
Phase 1
Modalities
Small molecule

ImmuneSensor Therapeutics General Information

Phase 1 trial of lead cGAS inhibitor IMSB301 initiated in healthy volunteers in Australia. First dose cohort completed with exposure levels and PK as predicted from preclinical studies.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

IMSA101
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to ImmuneSensor Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

ImmuneSensor Therapeutics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view ImmuneSensor Therapeutics's complete valuation and funding history, request access »

ImmuneSensor Therapeutics Investors

Not explicitly listed; received non-dilutive funding/grants including $16M CPRIT grant.
Investor Type: Venture Capital
Holding: Minority
Wheelhouse Life Science Advisors involved.
Investor Type: Venture Capital
Holding: Minority